8-K 1 d255045d8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 26, 2016

Minerva Neurosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware |  | 001-36517 |  | 26-0784194
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (I.R.S. Employer Identification No.)

1601 Trapelo Road Suite 284 Waltham, MA |  | 02451
(Address of principal executive offices) |  | (Zip Code)

(Registrant’s telephone number, including area code): (617) 600-7373

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01 | Other Events

On October 26, 2016, Minerva Neurosciences, Inc. (the “Company”) issued a press release announcing data from the 24-week open-label extension of its 12-week, randomized, double-blind, placebo-controlled Phase IIb clinical trial of MIN-101 as monotherapy in patients with negative symptoms of schizophrenia. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and a copy of the Company’s presentation that includes supporting data for the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01. | Financial Statements and Exhibits

(d) Exhibits

Exhibit No. |  | Description
99.1 |  | Press Release of the Company dated October 26, 2016
99.2 |  | Presentation of the Company dated October 26, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MINERVA NEUROSCIENCES, INC.
By: |  | /s/ Mark S. Levine
Name: |  | Mark S. Levine
Title: |  | Senior Vice President, General Counsel and Secretary

Date: October 26, 2016

INDEX OF EXHIBITS

Exhibit No. |  | Description
99.1 |  | Press Release of the Company dated October 26, 2016
99.2 |  | Presentation of the Company dated October 26, 2016